iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/23026359
Brain tumors - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Nov;42(6):356-70.
doi: 10.1053/j.semnuclmed.2012.06.001.

Brain tumors

Karl Herholz  1 , Karl-Josef Langen, Christiaan Schiepers, James M Mountz
Affiliations
Review

Brain tumors

Karl Herholz et al. Semin Nucl Med. 2012 Nov.

Abstract

This review addresses the specific contributions of nuclear medicine techniques, and especially positron emission tomography (PET), for diagnosis and management of brain tumors. (18)F-Fluorodeoxyglucose PET has particular strengths in predicting prognosis and differentiating cerebral lymphoma from nonmalignant lesions. Amino acid tracers including (11)C-methionine, (18)F-fluoroethyltyrosine, and (18)F-L-3,4-dihydroxyphenylalanine provide high sensitivity, which is most useful for detecting recurrent or residual gliomas, including most low-grade gliomas. They also play an increasing role for planning and monitoring of therapy. (18)F-fluorothymidine can only be used in tumors with absent or broken blood-brain barrier and has potential for tumor grading and monitoring of therapy. Ligands for somatostatin receptors are of particular interest in pituitary adenomas and meningiomas. Tracers to image neovascularization, hypoxia, and phospholipid synthesis are under investigation for potential clinical use. All methods provide the maximum of information when used with image registration and fusion display with contrast-enhanced magnetic resonance imaging scans. Integration of PET and magnetic resonance imaging with stereotactic neuronavigation systems allows the targeting of stereotactic biopsies to obtain a more accurate histologic diagnosis and better planning of conformal and stereotactic radiotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Left: Positron emission tomography (PET) scan with abnormality involving the right frontal lobe. Middle: Contrast magnetic resonance imaging (MRI) scan shows enhancement in the right frontal lobe. Right: There is a focal area of increased fluorodeoxyglucose (FDG) uptake involving the right frontal lobe consistent with a high-grade transformation and recurrence of tumor in the right frontal lobe 8 years after initial diagnosis and therapy. (Color version of figure is available online.)
Figure 2
Figure 2
Anaplastic astrocytoma, World Health Organization (WHO) grade III. (A) Multiple voxel spectra coregistered with postcontrast T1-weighted MRI. (B) Map of Cho/Cr demonstrates a focus of signal intensity in the right frontal lobe. Magnetic resonance spectroscopic imaging (MRSI) signal intensity is presented on a rainbow color scale where blue green is normal background and bright red corresponds to greatly elevated signal intensity. (C) Spectral analysis of the voxel demonstrating maximal Cho/Cr ratio. (D) T1-weighted MRI (postcontrast) demonstrating enhancing lesion in the right frontal lobe. (E) FDG-PET scan shows a focus of increased tracer activity greater than white matter in the right frontal lobe. (F) FDG-PET image coregistered with postcontrast T1-weighted MRI Reprinted with permission from Imani et al.
Figure 3
Figure 3
Oligoastrocytoma, WHO grade II: T1-weighted MRI after application of Gd-DTPA (A) shows no contrast enhancement. T2-weighted MRI scan (B) shows widespread abnormalities. (C) O-(2-18F-fluoroethyl)-l-tyrosine (18FFET-PET) identifies metabolically active areas within the tumor and indicates an optimal site for biopsy.
Figure 4
Figure 4
Inhomogeneous anaplastic astrocytoma, WHO grade III: T1-weighted MRI after application of Gd-DTPA (A) shows no contrast enhancement. T2-weighted MRI scan (B) shows widespread abnormalities. (C) 18F-FET-PET identifies a hot spot in the posterior part that cannot be identified on MRI. Biopsy in this area yielded an anaplastic astrocytoma, WHO grade III.
Figure 5
Figure 5
Glioblastoma (WHO grade IV) pretreated by surgery and radiochemotherapy. T1-weighted MRI after application of Gd-DTPA (A) and T2-weighted MRI (B) are ambiguous. (C) 18F-FET PET identifies pathologic tracer accumulation, which was confirmed as tumor recurrence. (Color version of figure is available online.)
Figure 6
Figure 6
Composite images of frames summed between 50 and 60 minutes. The patient was a 37-year-old woman with a glioblastoma multiforme in the left insular and temporal opercular regions, who was treated with irinotecan and bevacizumab in 2-week cycles. Representative transaxial slices of the tumor are shown. All images are scaled to the same maximum concentration in Bq/mL. The initial 18F-FLT uptake is high at baseline (left), drops after 2 weeks of therapy (middle), and remains similar after 6 weeks (right); the respective standardized uptake values (SUV75%) were 1.154, 1.075, and 1.076. Progression-free survival and overall survival were found to be 304 days and 460 days, respectively. (Color version of figure is available online.)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215–225. discussion 226-219. - PubMed
    1. Reivich M, Kuhl D, Wolf A, et al. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979;44:127–137. - PubMed
    1. Hustinx R, Smith RJ, Benard F, et al. Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur J Nucl Med. 1999;26:1501–1509. - PubMed
    1. Spence AM, Muzi M, Mankoff DA, et al. 18F-FDG PET of gliomas at delayed intervals: Improved distinction between tumor and normal gray matter. J Nucl Med. 2004;45:1653–1659. - PubMed
    1. Prieto E, Martí-Climent JM, Domínguez-Prado I, et al. Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation. J Nucl Med. 2011;52:865–872. - PubMed

Substances